English
全部
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
搜索
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
1 天
辉瑞新一代PD-L1靶向抗体药物在中国获得临床批准
近日,辉瑞(Pfizer)公司旗下的Seagen宣布,其新研发的1类抗癌药物PF-08046054获得了中国国家药品监督管理局(CDE)的临床试验默示许可。这款药物以PD-L1为靶点,属于抗体偶联药物(ADC)类型,具有创新性,旨在治疗转移性或不可切除的晚期实体瘤。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Hits correction territory
Ordered to reinstate workers
CDC nomination withdrawn
Police charge stepmother
Sister receives bomb threat
Asks SCOTUS to intervene
Out as creative director
Texas Tech closes campus
Urges US to move nukes
Ditch new stadium deal
Indonesian fishermen sue
NY migrant hotels probe
Ex-TX church pastor indicted
Idaho adopts firing squad
Schumer on funding bill
Acne treatments recalled
Total lunar eclipse tonight
Former NBA center dies
Protective order for accuser
New moons orbiting Saturn
Marks 12th anniversary
200% tariff on EU alcohol?
Says he supports ceasefire
To test Community Notes
Wholesale prices unchanged
States sue to block layoffs
IRS demotes chief counsel
Won't run for Senate in MI
Weekly jobless claims fall
反馈